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Lynch syndrome is an autosomal dominant cancer pre-
disposition syndrome which is caused by a germline
mutation in one of four genes, MLH1, MSH2, MSH6
or PMS2. Individuals with a germline mutation in one
of these genes are at increased lifetime risk of colon,
endometrial, ovarian, small intestine, renal pelvis and
ureter. Less commonly patients may develop biliary
tract cancers, gastric and pancreatic cancers, brain
tumours, sebaceous adenomas, carcinomas and skin
keratoacanthomas.
Immunohistochemical staining for the above four mis-
match repair (MMR) proteins is routinely performed for
individuals with bowel cancer or a related cancer who
are suspected of having Lynch syndrome. This helps tar-
get genetic testing to the correct mismatch repair gene.
The genes involved in Lynch syndrome work together in
a DNA repair complex. The MMR proteins form a het-
erodimer with MLH1 partnering PMS1, PMS2 or MLH3
and MSH2 partnering MSH3 or MSH6. This means that
a mutation in MLH1 leads to loss of staining of both
MLH1 and PMS2, while a mutation in MSH2 leads to
loss of staining of both MSH2 and MSH6. The same is
not true however, for mutations in either PMS2 or
MSH6, where only the single protein made by these
genes is not expressed in the tumour.
However, the pattern of staining using immunohisto-
chemistry is sometimes more complex due to coding
microsatellites within the MSH6 gene. We present two
unrelated cases with a germline PMS2 mutation which
had loss of both MSH6 and PMS2, but normal MLH1
and MSH2 on immunohistochemical staining.
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